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Abstract
In the present study, cellular tropism and relative transduction efficiency of AAV2/6, AAV2/8 and
AAV2/9 vectors have been tested for the cornea using primary cultures of human corneal fibroblasts.
The AAV6, AAV8 and AAV9 serotypes having AAV2 ITR plasmid encoding for alkaline
phosphatase (AP) gene were generated by transfecting HEK293 cell line with pHelper, pARAP4 and
pRep/Cap plasmids. Primary cultures of human corneal fibroblasts were exposed to AAV infectious
particles at two different doses (1×105 and 2×105 MOI). Cytochemistry and enzyme assays were
used to measure delivered transgene expression in samples collected at 4 and 30 hours after AAV
infection by counting AP-stained cells or quantifying AP enzyme activity. Cellular toxicity of AAVs
was evaluated with TUNEL and trypan blue assays. All three AAV serotypes transduced human
corneal fibroblasts. The order of transduction efficiency was AAV2/6>>>AAV2/9>AAV2/8. The
transduction efficiency of AAV2/6 was 30-50 fold higher (p <0.001) for the human corneal
fibroblasts compared to the AAV2/8 or AAV2/9 at two tested doses. The level of transgene
expression at 4 hrs was considerably low compared to 30 hrs suggesting that the transgene delivery
did not reach its peak at 4 hrs. Cultures exposed to any of the three AAV serotypes showed more
than 97% cellular viability and less than 5 TUNEL positive cells suggesting that tested AAV
serotypes do not induce significant cell death and are safe for corneal gene therapy.
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1. Introduction
Efficient delivery of therapeutic levels of transgene in the cells/tissues is critical for treating
patients with gene therapy. Numerous viral and non-viral vectors have been developed and
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tested for this purpose. Among recombinant viral vectors, adeno-associated virus (AAV) has
emerged as a promising vector for delivering genes efficiently in the ocular cells [15,18,22,
27]. AAV has the ability to transduce dividing as well as non-dividing cells and to extend long-
term transgene expression. Further, their non-pathogenicity to humans enables them to be an
attractive vector for clinical gene therapy. More than 100 serotypes of AAV are known but
serotypes 1-9 have been extensively tested for gene therapy [2,25]. The bulk of studies
evaluated efficiency of AAV serotypes 2 and 5 for delivering genes in the retina and showed
varied degree of transgene delivery into photoreceptors and retinal pigment epithelial cells of
rodent, canine and primate retinas in vivo [2,25]. Further, AAV2 has been widely used in
preclinical and clinical trials for many retinal diseases including ocular albinism, retinitis
pigmentosa and Leber congenital amaurosis [3,16,25]. Contrary to retinal gene therapy, few
studies have been performed to evaluate usefulness of AAV vectors for corneal gene therapy
[15,19,20]. Our previous studies demonstrated efficacy of AAV2 and AAV5 to deliver genes
into the rabbit and rodent stroma in vivo [19,20,23]. The delivered transgene expression
appeared 3 days after vector application and continued for up to 10 days or longer. Our
subsequent gene transfer studies discovered that delivery of therapeutic genes could be targeted
into the stroma by administering the vector in combination with newly-optimized topical and
microinjection vector-delivery techniques [20,23]. Other investigators also showed transgene
delivery in the rodent corneas with AAV vector [6,11]. Recently, Liu et al compared efficiency
of recombinant adenovirus and AAV vectors for delivering genes in the rabbit and human
corneal cells (15).
Accumulating evidence suggests that capsid protein is a major determinant of cellular tropism
and transduction efficiency of AAV [26]. Thus, many hybrid AAV vectors have been
engineered using capsid protein of AAV serotypes 1-9 and genome of AAV serotype 2. Many
investigators tested efficiency of hybrid AAV vectors for delivering transgene into ocular and
non-ocular tissues using in vitro and in vivo models [2,4,5,13,15,25,29]. Among hybrid AAV
vectors, AAV 2/5 has been tested in abundance for delivering genes in the retina [25] and the
cornea [20], and has shown considerably enhanced transgene delivery in these ocular tissues
compared to the AAV2 [20,25]. Recently, hybrid vectors AAV2/8 and AAV2/9 have been
reported to have up to 5- 100 fold higher efficiency for transgene delivery as compared to
AAV2 serotypes in cardiac muscle [4,29], brain [5], skeletal muscle [29], lung [13] and liver
[7]. For the ocular tissue, hybrid vectors derived from eight AAV serotypes have been tested
for transgene delivery in the retina by several research groups [2,12,25]. Interestingly, AAV2/1,
AAV2/4 and AAV2/6 vectors have shown higher transduction efficiency for retinal pigmented
epithelium than AAV2/5. However, AAV2/5 had more robust expression in the photoreceptors
[25]. On the other hand AAV2/7, AAV2/8 and AAV2/9 showed equal preference for retinal
pigmented epithelium and photoreceptors [25] suggesting that hybrid AAV vectors possess
unique cellular tropism for different cell types/tissues.
Clinical application of AAV2 vector can be compromised due to the presence of AAV2
neutralizing antibodies in humans. This concern can be minimized by the use of non-human
primate derived AAV7 and AAV8 serotypes [8]. Thus, AAV2/7 and AAV2/8 hybrid vectors
were developed and found effective for transgene delivery in tissues [12,25]. However, efficacy
of several newly developed hybrid AAV vectors has not been tested for the cornea. In this
study we examined and compared the efficiency of hybrid AAV2/6, AAV2/8 and AAV2/9
vectors for delivering genes in the cornea using an in vitro model.
2. Materials and methods
2.1. Human corneal fibroblast culture
Primary cultures of human corneal fibroblasts (HSF) were generated from donor corneas
procured from Heartland Eye Bank, St. Louis, Missouri, using previously reported methods
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[28]. Briefly, the cornea was washed with HSF medium, and the epithelium and endothelium
were removed by gentle scraping with a scalpel blade. The corneal stroma was cut into small
pieces and incubated in humidified CO2 incubator at 37 °C in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum to obtain HSF.
2.2. AAV vector production
Plasmids for AAV6 rep/cap (pCMV-Cap6, pMT-Rep2) and AAV genomic plasmid (pARAP4)
were a generous gift from Dr Dusty Miller, Fred Hutchison Cancer Research Center, Seattle,
WA. AAV8 and AAV9 rep/cap plasmids (pAAV2/8; pAAV2/9) were gifted by Dr James M.
Wilson, Gene Therapy Program, Division of Medical Genetics, Department of Medicine,
University of Pennsylvania, Philadelphia, PA. AAV vector was generated using adenovirus
free system following previously published protocol [9]. Briefly, human embryonic kidney
(HEK) 293 cells were co-transfected with AAV2-based genomic vector pARAP4, AAV Rep/
Cap plasmids and adenovirus helper plasmid (pHelper; Stratagene La Jolla, CA, catalogue #
240071). pARAP4 expresses heat stable placental alkaline phosphatase (AP) under the
regulation of Rous sarcoma virus (RSV) promoter/enhancer and simian virus 40 (SV40)
polyadenylation sequence. AAV6 was generated using four plasmids, viz. pHelper, pCMV-
Cap6, pMT-Rep2 and pARAP4. These plasmids were used at a ratio of 3:3:1:1 respectively.
For AAV 8 and AAV9 production, pAAV2/8 and pAAV2/9 encoding for AAV2rep and AAV8
or AAV9cap were used along with pHelper and pARAP4 at a ratio of 3:3:1, respectively. The
virus containing cell lysate was harvested at 62 hrs post-transfection. Recombinant viral stocks
were purified by two sequential rounds of CsCl gradient ultracentrifugation. Collected viral
fractions were pooled and dialyzed through two rounds of HEPES-buffered saline. Viral titer
was determined by dot blot analysis using DIG labeled probes (Roche Applied Science,
Indianapolis, IN).
2.3. Transduction of human corneal fibroblasts with AAV vectors
Seventy-percent confluent cultures of HSF in 12-well plates were used for the experiments.
Three wells for each viral vector transduction were used in every experiment. Cultures were
serum-deprived for 2 hours prior to viral transduction (Viral titer 109genomic copies/μl) and
were exposed to viral vectors in serum free medium at a multiplicity of infection (MOI) of
105 and 2 × 105. After 6 hours, the medium containing the viral vector was replaced with the
fresh serum-containing medium, and cells were incubated for 4 or 30 hours prior to alkaline
phosphatase (AP) quantification.
2.4. Cytochemical quantification of alkaline phosphatase
Cultures were washed twice with PBS, fixed in 0.5% glutaraldehyde for 30 min followed by
three PBS washes, and 30 min incubation at 65°C in 1mM MgCl2 in PBS to inactivate heat-
labile endogenous AP. Cytochemical staining was performed by incubating the cultures with
a mixture of BCIP (5-Bromo-4-Chloro-3′-Indolyphosphate p-Toluidine) and NBT (Nitro-Blue
Tetrazolium) at 37°C for 2 hrs. The AP-stained cells appeared as dark blue. AP-stained cells
were quantified at 100× magnification in six randomly selected, non-overlapping areas of each
well.
2.5. Spectrophotometric measurement of alkaline phosphatase in cell lysates
Cell lysates were prepared using RIPA buffer (Tris 50mM, NaCl 150mM, NP40 1%, Na-
deoxycholate 0.5% containing 1× Roche protease inhibitor). The protein content for each
sample was determined using the Bradford method. AP activity in cell lysates was determined
by a spectrophotometric assay using StemTAG Alkaline Phosphatase Activity Assay Kit (Cell
Biolabs, Inc., San Diego, CA) following manufacturer’s protocol. Controls included a blank
with no cell lysate and cell lysate from uninfected cells. Assay for each sample was run in
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duplicate and the optical density for AP activity was read at 405 nm. p-nitrophenol was used
for plotting the standard curve. The AP activity was expressed as μM of p-nitrophenol
generated/μg protein.
2.6. Cellular viability and apoptosis evaluation
To detect the possibility of fibroblast apoptosis due to AAV vector transfection, cells were
fixed in paraformaldehyde at room temperature for 5 min and then washed in PBS. A
fluorescence-based TUNEL assay was used according to the manufacturer’s instructions using
ApopTag apoptosis detection kit (Chemicon international, Temecula, CA, USA). The effect
of AAV treatment on cell viability was assessed using trypan blue assay. Briefly, cell
suspension was mixed with an equal volume of 0.4% trypan blue solution (Invitrogen, San
Diego, CA)) and blue stained and unstained cells were counted using a hemocytometer to
calculate the percentage of viable cells.
2.7. Statistical analysis
The results were expressed as mean ± standard error of the mean (SEM). Statistical analysis
was performed using two-way analysis of variance (ANOVA) followed by Bonferroni test for
comparing data between different AAV vectors. For comparing different doses or time points
one way ANOVA followed by Tukey’s multiple comparison test was used.
3. Results
3.1. Characterization of gene delivery by AP cytochemical staining
All three tested AAV serotypes successfully transduced human corneal fibroblasts. Fig. 1
demonstrates levels and localization of delivered transgene in human corneal fibroblasts. Thirty
hours after AAV treatment, AAV2/6, AAV2/8 or AAV2/9 vector at 1×105 MOI dose showed
substantial delivery of AP gene in HSF compared to the control (p<0.001). The AAV2/6
serotype showed highest transduction efficiency followed by AAV2/9 and AAV2/8. The
quantification of AP-stained cells in the cultures was performed to determine relative
transduction efficiency of the tested AAV serotypes and has been shown in Fig. 2. As evident
from the data, all the tested serotypes efficiently transduced HSF and showed statistically
significant transgene delivery into human corneal fibroblasts compared to control samples. The
AAV2/6 showed highest and AAV2/8 showed lowest transgene delivery. The relative
efficiency of the three vectors was AAV2/6, AAV2/9 and AAV2/8. The AAV2/6-treated
cultures showed statistically significant 32 fold higher transgene delivery (p<0.001) compared
to AAV2/8 and 23 fold higher compared to AAV2/9. Comparative analysis between the AAV
2/8 and AAV2/9 revealed that 1.3 fold higher transgene was delivered by AAV2/9 than
AAV2/8 in HSF. Nonetheless, the difference in the levels of transgene delivery between
AAV2/8 and 2/9 was not statistically significant probably due to the low levels of transduction
with these two AAV serotypes.
The transduction efficiency of AAV depends on viral concentration. To test whether virus
concentration affects transgene delivery in HSF, we doubled the dose of AAV (2×105 MOI)
and compared the transduction efficiency of AAV2/6, AAV2/8 and AAV2/9 for the cornea in
vitro. The gene transfer data collected 30 hrs after AAV2/6, AAV2/8 or AAV2/9 serotype
infection at the dose of 2×105 MOI confirmed that levels of transgene delivery in the cornea
is influenced by the AAV titer. As evident from Figs. 2 and 3, AAV2/6 demonstrated a 2.2
fold increase (p< 0.001) in transduction levels at higher dose (2×105 MOI) compared to the
lower dose (1×105 MOI). Similarly, AAV2/8 and AAV2/9 showed a 1.5 and 1.7 fold increase,
respectively, in transduction levels at high dose compared to their lower doses. However, this
increase was not statistically significant. Furthermore, at high dose transduction efficiency of
AAV2/6 was 50 fold more than the same dose of AAV2/8 (p<0.001) or AAV2/9 (p<0.001).
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Various AAV serotypes have shown different onset-timing for delivered-transgene. To insure
that the order of transduction efficiency observed for the three tested AAV serotypes for the
cornea was not because of the different onset-timing, we measured the AAV2/6, AAV2/8 and
AAV2/9 delivered transgene expression in the HSF at an additional randomly selected time
point of 4 hours. Qualitative and quantitative analyses of data collected at 4 hrs showed that
order of transduction efficiency for the tested AAV serotypes remained the same
(AAV2/6<AAV2/9<AAV2/8). However, the total amount of delivered-transgene at 4 hrs was
considerably lower than at 30 hrs (data not shown). Another difference observed at the 4 hrs
time point was that AAV2/6 showed only 20 fold higher transduction efficiency compared to
AAV2/8 or AAV2/9 instead of the 50 fold increase noted at 30 hrs (data not shown). This
observation suggests that AAV2/6 mediated transgene delivery did not reach to its peak at 4
hrs.
3.2. Quantification of gene delivery by AP enzyme assay
The gene transduction efficiency of the three selected AAV serotypes was also analyzed by
quantifying AP enzyme activity in control and AAV-treated samples. Figure 4 shows levels
of enzyme activity measured in cell lysates prepared 30 hrs after exposing HSF cultures at low
(1×105 MOI) or high (2×105 MOI) AAV2/6, AAV2/8 or AAV2/9 doses. As evident from Fig.
4, all the three tested serotypes demonstrated significantly more enzyme activity than the
control samples (p <0.001 or 0.01). AAV2/6-treated samples showed 2.2 fold more enzyme
activity at low dose and 2.8 fold more enzyme activity at high dose compared to their
corresponding control groups whereas AAV2/8 and AAV2/9 showed statistically insignificant
0.3 fold increase in AP activity compared to the lower dose (Fig. 4). The comparative analysis
of AP activity in cell lysates prepared 30 hrs after high dose (2×105 MOI) treatment of AAV2/6,
AAV2/8 or AAV2/9 showed that AAV2/6 serotype was 22 fold (p <0.001) more efficient than
the AAV2/9 serotype and 28 fold (p <0.001) more efficient than the AAV2/8 serotype (Fig.
4). On the other hand, samples of AAV2/8 and AAV2/9 serotypes showed insignificant (<0.1-
fold) difference in AP enzyme activity.
3.3. Effect of AAV2/6, AAV2/8 and AAV2/9 on cellular viability and death
The effect of two tested doses of selected AAV serotypes on HSF viability and death was also
investigated. None of the tested doses of the three selected AAV serotypes caused significant
loss of cellular viability or induced cell death. Cultures exposed to AAV2/6, AAV2/8 or
AAV2/9 showed over 97% viable cells at both the tested AAV doses (1×105 MOI and
2×105 MOI). This viability was comparable to control groups suggesting that selected AAV
serotypes do not significantly affect HSF viability. Figure 5 shows results of TUNEL assay
which primarily detects apoptosis and to a lesser extent necrosis. Less than 5 TUNEL-positive
cells were detected in the control, AAV2/6, AAV2/8 or AAV2/9 treated HSF cultures at two
tested doses (1×105 MOI and 2×105 MOI) suggesting that tested AAV serotypes do not induce
cell death and are safe for corneal gene therapy. A representative image of TUNEL staining
for AAV2/6 treated HSF cultures is shown in Fig. 5.
Discussion
AAV serotype 2 has been shown to transport foreign genes efficiently into the cornea, retina
and other ocular tissues [2,20,25]. Besides AAV2, many hybrid AAV vectors have been
developed and tested for delivering genes in various tissues including the eye [2,15,24]. Hybrid
AAV vectors have shown increased transduction efficiency and safety standards compared to
AAV2. Nonetheless, these vectors have exhibited unique tropism and showed different
transduction efficiency for various tissues/cells. Bish et al [4] found AAV2/9 hybrid vector
most efficient for delivering genes in the heart compared to the AAV2/1, AAV2/6, AAV2/7,
and AAV2/8. However, AAV2/8 showed up to 200 fold higher transgene delivery in liver
Sharma et al. Page 5













compared to AAV2 [7]. On the other hand, AAV2/6 vector was more efficient for delivering
genes in the muscle than AAV2/5 or AAV2 vectors [9]. Similar pattern of differences in the
transduction efficiency of AAV have been reported for the ocular tissues. The AAV2/5 vectors
showed significantly more transgene delivery than AAV2 in corneal stroma, photoreceptors
and retinal pigmented epithelium [20,25]. Recently, hybrid AAV2/1, AAV2/6 and AAV2/4
vectors were found more efficient than the AAV2 for retinal pigmented epithelium [25]. The
transduction efficiency of AAV2/2 and AAV2/5 serotypes for delivering genes in the mouse
cornea has been examined previously [19,20]. However, transduction efficiency of AAV2/6,
AAV2/8 and AAV2/9 has not been tested for cornea so far. In this study we report the ability
of AAV2/6, AAV2/8 and AAV2/9 vectors to deliver genes in the cornea and demonstrate the
relative transduction efficiency of these vectors for delivering therapeutic genes in human
corneal fibroblasts. Amongst the three tested serotypes, AAV2/6 showed several folds higher
transduction efficiency as compared to AAV2/8 or AAV2/9 for gene delivery in HSF.
Both, in vivo and in vitro models have been used for evaluating transduction efficiency of AAV
vectors. The transduction efficiency exhibited by several hybrid AAV vectors for many
cultured cells such as lung epithelium, skeletal muscle, gastrointestinal tract cells, etc. was
found comparable to the levels of delivered-transgene in vivo [9,14,21] suggesting that in
vitro model can provide useful information regarding the efficacy of AAV vectors.
Additionally, in vitro models are economical, easily-manageable and allow precise control of
experimental conditions for all the groups. Thus, for the initial testing of selected AAV vectors
and comparing their transduction efficiencies for the cornea, human corneal fibroblast primary
cultures were used. Nonetheless, the findings of the in vitro studies need to be revalidated by
the in vivo experiments as multiple studies have reported discrepancy in the amount of
transgene delivery in vitro and in vivo [10]. Moreover, the importance of in vivo screening can
be realized by the fact that laminin receptor expression (integrin α3β1 and α6β1) has not been
found to be the same in adherent and suspension cultures of human corneal fibroblasts [17,
24]. The low levels of laminin receptors in cultured corneal fibroblasts may be a contributing
factor for low transgene delivery by the AAV2/8 and AAV2/9 vectors as both of these AAV
serotype have been reported to use these receptors for entering inside the cell [1]. Besides
receptor expression, AAV-mediated gene transfer may also be affected by factors such as lack
of endosomal processing, nuclear transport, uncoating, transcription and translation of gene
products, etc.
The capsid plays an important role in AAV-mediated gene transfer. It is a primary interface
between the host and the vector genome, and is involved in cell binding, internalization and
trafficking within the target cell. The capsid influences AAV specificity, transduction
efficiency and biodistribution in the tissue [26]. The difference in the transduction efficiency
of various AAV vectors has been attributed to the capsid. Subretinal injection of AAV2/4 has
preferentially delivered more transgene than AAV2 in the retinal pigment epithelium whereas
AAV5 and AAV6 primarily delivered genes in the lung airways cells and AAV9 in alveolar
cells [13,14]. On the other hand, AAV6, AAV8 and AAV9 showed robust transgene delivery
in muscles in vivo [4,9,29]. Some investigators have identified the involvement of various
receptors present on the target cells that might have an effect on cellular tropism and
transduction efficiency of AAV. Using lectin competition assays, Wu et al., [30] demonstrated
that high transduction efficacy of AAV6 for the skeletal and cardiac tissue compared to AAV8
or AAV9 is due to the involvement of α2,3- or α2,6-linked sialic acid receptor for the cellular
entry. The AAV6 uses α2,3- or α2,6-linked sialic acid receptor whereas AAV2/8 and AAV2/9
use laminin receptors. Since the three AAV vectors used in this study carried the same AAV2
ITR plasmid encoding for alkaline phosphatase, it is reasonable to conclude that observed
differences in transduction efficiency of AAV2/6 and AAV2/8 or AAV2/9 for human corneal
fibroblasts noted in this study are because of different capsid properties.
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In conclusion, tested hybrid AAV2/6, AAV2/8 and AAV2/9 vectors efficiently delivered
foreign genes in the cornea in vitro. The amount of delivered-transgene in the cornea depends
on serotype as AAV2/6 vector showed several fold higher gene transduction for the human
corneal fibroblasts compared to AAV2/8 or AAV2/9. This study provides useful information
regarding serotype selection for preclinical corneal gene therapy studies.
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Transduction efficiency of AAV2/6, AAV2/8 and AAV2/9 for human corneal fibroblasts.
Representative images showing alkaline phosphatase (AP) cytochemical staining 30 hours
after viral vector application at MOI 1×105. Scale bar denotes 200 μm.
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Transduction efficiency of AAV2/6, AAV2/8 and AAV2/9 for human corneal fibroblasts.
Representative images showing alkaline phosphatase (AP) cytochemical staining 30 hours
after viral vector application at MOI 2×105. Scale bar denotes 200 μm.
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AAV2/6, AAV2/8 and AAV2/9-mediated gene transfer quantification in human corneal
fibroblasts. Alkaline phosphatase (AP)-stained cells were counted in 100× magnification 30
hours after viral vector application at MOI 1×105and 2×105.
*p<0.05 vs control; ** p<0.001 vs control or AAV2/8 or AAV2/9 # p<0.001 vs 105 MOI
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AAV2/6, AAV2/8 and AAV2/9-mediated gene transfer in human corneal fibroblast cell
lysates. Alkaline phosphatase (AP) was quantified using enzyme assay 30 hours after viral
vector application at MOI 1×105and 2×105.
*p<0.01 vs control; ** p<0.001 vs control or AAV2/8 or AAV2/9 # p<0.001 vs 105 MOI
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TUNEL assay of human corneal fibroblasts (HSF) treated with AAV2/6. Nuclei are stained
blue with DAPI. Few TUNEL-positive cells (Red) were seen in both the control and AAV
treated HSF. Scale bar denotes 100 μm. The AAV2/8 or AAV2/9 vcetor treatment to HSF also
did not cause significant cell death (Data not shown).
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